China Approval Watch: September Dominated By Generics And Vaccines
Executive Summary
Twenty-three chemical drugs, three biologics and one traditional Chinese medicine are among the latest approvals granted by the China FDA, which is continuing on a hiring spree to increase its number of reviewers.
You may also be interested in...
China Regulatory Watch: New Fast-Track Designations, CTAs
China Regulatory Watch is our new snapshot of product-specific regulatory developments at the China FDA.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.